<DOC>
	<DOCNO>NCT00312000</DOCNO>
	<brief_summary>Primary objective : To assess efficacy , define overall survival , sequential versus combination chemotherapy advance colorectal cancer ( CRC ) . Methodology Open , randomise multicenter phase III study . Randomisation centre centralize . 820 patiÃ«nts histologically proven advanced CRC ; amenable curative surgery . Measurable evaluable disease . Age 18 year . WHO performance status 0-2 . Test product : Arm A : First line : capecitabine capecitabine 1250 mg/m2 orally b.i.d . day 1-14 ( q3 ) , progression unacceptable toxicity . Second line : irinotecan 350 mg/m2 IV infusion day 1 ( q3 ) , progression unacceptable toxicity . Third line : oxaliplatin 130 mg/m2 IV infusion day 1 capecitabine 1000 mg/m2 orally b.i.d . day 1-14 ( q3 ) . Arm B : First line : irinotecan 250 mg/m2 IV infusion 30 minute day 1 capecitabine 1000 mg/m2 orally b.i.d . day 1-14 ( q3 ) , progression unacceptable toxicity . Second line : oxaliplatin 130 mg/m2 IV day 1 capecitabine 1000 mg/m2 orally b.i.d . day 1-14 ( q3 ) , progression unacceptable toxicity . Patients follow CT-scan every 9 week response treatment , moment progression suspect . After cessation chemotherapy , patient follow every 3 month death . Clinical laboratory toxicity/symptomatology grade accord NCI common criterion .</brief_summary>
	<brief_title>Sequential Versus Combination Chemotherapy Advanced Colorectal Carcinoma</brief_title>
	<detailed_description>Objectives : Primary objective : To assess efficacy , define overall survival , sequential versus combination chemotherapy advance CRC . Secondary objective ass : To assess Tumour response ( CR , PR SD ) Progression free survival Quality life Toxicity profile Methodology Open , randomise multicenter phase III study . Randomisation centre centralize IKC . Number patient 820 Main criterion inclusion Histology stag disease - Histologically proven advanced CRC ; amenable curative surgery ; - Of Note : In case single metastasis , histological cytological proof colorectal carcinoma obtain prior randomisation . - Measurable evaluable disease . Serum CEA parameter disease activity allow . General condition - Written informed consent ; - Age 18 year ; - WHO performance status 0-2 ; - Adequate bone marrow function ( WBC &gt; 3.0 x 109/L , platelet &gt; 100 x 109/L , Hb &gt; 6 mmol/L ) ; - Adequate hepatic function : total bilirubin &lt; 1 . 5 x upper normal limit , ASAT ALAT &lt; 3 x upper normal limit ( case liver metastases &lt; 5 x upper normal limit ) ; - Adequate renal function : creatinin &lt; 1 . 5 x upper normal limit . Other - Expected adequacy follow-up . Main criterion exclusion General condition - Pregnancy lactation ; - Patients ( M/F ) reproductive potential implementing adequate contraceptive measure . Prior current history - Prior chemotherapy advance disease ; prior adjuvant chemotherapy allow , provide last drug administration take place 6 month prior randomisation . - Serious concomitant disease prevent safe administration chemotherapy likely interfere study assessment ; - Serious active infection ; - Inflammatory bowel disease disease associate chronic diarrhoea ; - Previous extensive irradiation pelvis abdomen ; - Other malignancy past 5 year exception adequately treat carcinoma situ cervix squamous basal cell carcinoma skin . Concomitant treatment - Concomitant ( within 4 week randomisation ) administration experimental drug investigation ; - Concurrent treatment anti-cancer therapy . Test product , dose mode administration Arm A First line : capecitabine Every 3 week ( q 3 ) : capecitabine 1250 mg/m2 orally b.i.d . day 1-14 . This schedule continue progression unacceptable toxicity . Continuation 6 month without disease progression and/or severe toxicity investigator 's discretion . Second line : irinotecan Every 3 week ( q 3 ) : irinotecan 350 mg/m2 IV infusion day 1 . This schedule continue progression unacceptable toxicity . Continuation 6 month without disease progression and/or severe toxicity investigator 's discretion . Third line : oxaliplatin plus capecitabine oxaliplatin 130 mg/m2 IV infusion day 1 capecitabine 1000 mg/m2 orally b.i.d . day 1-14 . This schedule continue progression unacceptable toxicity . Continuation 6 month without disease progression and/or severe toxicity investigator 's discretion . Arm B First line : irinotecan plus capecitabine Every 3 week ( q 3 ) : irinotecan 250 mg/m2 IV infusion 30 minute day 1 2 hour discontinuation infusion follow capecitabine 1000 mg/m2 orally b.i.d . day 1-14 . This schedule continue progression unacceptable toxicity . Continuation 6 month without disease progression and/or severe toxicity investigator 's discretion . Second line : oxaliplatin plus capecitabine Every 3 week ( q 3 ) : oxaliplatin 130 mg/m2 IV infusion 2 hour day 1 capecitabine 1000 mg/m2 orally b.i.d . day 1-14 . This schedule continue progression unacceptable toxicity . Continuation 6 month without disease progression and/or severe toxicity investigator 's discretion . Duration treatment follow-up Treatment continue disease progression , unacceptable toxicity . Patients follow CT-scan every 9 week response treatment , moment progression suspect . After cessation chemotherapy , patient follow every 3 month death . Death progression report whenever occurs . Criteria evaluation Efficacy All patient include survival analysis ( intent-to-treat ) . All patient receive &gt; 9 week treatment ( i.e . 3 cycle ) consider evaluable response , unless document progression occur earlier . Safety profile Safety analyse treatment group . Patients receive &gt; treatment dos evaluable toxicity . Evaluation perform patient cycle intent-to-treat population . Clinical laboratory toxicity/symptomatology grade accord NCI common criterion . The adverse event report NCI common criterion grade : mild , moderate , severe , life threatening . Statistical methodology The expected median survival Arm A ( standard arm ) 14 month . It anticipate median survival Arm B ( experimental arm ) 19 month . 620 patient ( 310 arm ) need show increase median survival ( &gt; =0,05 &gt; =0,80 ) . Stratification parameter Patients stratify follow parameter : - WHO performance status 0-1 v 2 - Serum LDH normal versus normal - Prior adjuvant therapy versus prior adjuvant therapy - Predominant localisation metastasis liver vs extrahepatic site ( ) - Per participate institution</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histology stag disease Histologically proven CRC ; advanced disease , amenable curative surgery ; Of Note : In case single metastasis , histological cytological proof colorectal carcinoma obtain prior randomisation . Measurable evaluable disease ; Serum CEA parameter disease activity allow . General condition Written inform consent ; Age 18 year ; WHO performance status 02 ; Adequate bone marrow function ( WBC &gt; 3.0 x 109/L , platelet &gt; 100 x 109/L , Hb &gt; 6 mmol/L ) ; Adequate hepatic function : total bilirubin &lt; 1 . 5 x upper normal limit , ASAT ALAT &lt; 3 x upper normal limit ; case liver metastases &lt; 5 x upper normal limit Adequate renal function : creatinin &lt; 1 . 5 x upper normal limit . Other Expected adequacy followup . General condition Pregnancy lactation ; Patients ( M/F ) reproductive potential implementing adequate contraceptive measure . Prior current history Prior chemotherapy advance disease ; prior adjuvant chemotherapy allow provide last administration give &gt; 6 month prior randomisation . Serious concomitant disease prevent safe administration chemotherapy likely interfere study assessment ; Serious active infection ; Inflammatory bowel disease disease associate chronic diarrhoea ; Previous extensive irradiation pelvis abdomen ; Other malignancy past 5 year exception adequately treat carcinoma situ cervix squamous basal cell carcinoma skin . Concomitant treatment Concomitant ( within 4 week randomisation ) administration experimental drug investigation ; Concurrent treatment anticancer therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>capecitabine</keyword>
	<keyword>irinotecan</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>